• 1. Examination of deposit in commercial diluted phosphoric acid
  Analyst, 1880,5, 146-147
• 2. Establishing the accuracy of position-specific carbon isotope analysis of propane by GC-pyrolysis-GC-IRMS
  ChangjieLiu,PengLiu,XiaofengWang,XiaoqiangLi,JuskeHorita
• 3. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245
• 4. Essential effect of the electrolyte on the mechanical and chemical degradation of LiNi0.8Co0.15Al0.05O2 cathodes upon long-term cycling??
  Xiaoming Liu,Zachary D. Hood,Wangda Li,Donovan N. Leonard,Arumugam Manthiram,Miaofang Chi J. Mater. Chem. A, 2021,9, 2111-2119
• 5. Emerging 2D hybrid nanomaterials: towards enhanced sensitive and selective conductometric gas sensors at room temperature
  Hanie Hashtroudi,Ian D. R. Mackinnon J. Mater. Chem. C, 2020,8, 13108-13126

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Halobenzenes Fluorobenzenes

Research Brief on (1S)-1-(3-chloro-4-fluorophenyl)ethan-1-amine (CAS: 2413817-92-0)

The compound (1S)-1-(3-chloro-4-fluorophenyl)ethan-1-amine (CAS: 2413817-92-0) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its potential as a chiral building block for the synthesis of biologically active molecules. This research brief aims to summarize the latest findings and developments related to this compound, focusing on its synthesis, applications, and pharmacological relevance.

Recent studies have highlighted the importance of (1S)-1-(3-chloro-4-fluorophenyl)ethan-1-amine as a key intermediate in the synthesis of novel drug candidates. Its chiral nature and structural features make it particularly valuable for the development of enantioselective pharmaceuticals. A 2023 study published in the Journal of Medicinal Chemistry demonstrated its utility in the synthesis of potent kinase inhibitors, showcasing its role in targeting specific signaling pathways involved in cancer progression.

The synthesis of (1S)-1-(3-chloro-4-fluorophenyl)ethan-1-amine has been optimized through asymmetric catalytic methods, as reported in a recent Organic Letters publication. Researchers employed a chiral palladium catalyst to achieve high enantiomeric excess (ee > 99%), significantly improving the efficiency and scalability of the process. This advancement is critical for large-scale pharmaceutical production, where enantiopurity is often a regulatory requirement.

Pharmacological evaluations of derivatives containing this amine moiety have revealed promising therapeutic potential. For instance, a series of compounds incorporating (1S)-1-(3-chloro-4-fluorophenyl)ethan-1-amine exhibited potent activity against neurodegenerative targets, as evidenced by in vitro and in vivo studies. These findings were presented at the 2024 American Chemical Society National Meeting, suggesting potential applications in Alzheimer's disease treatment.

Structural-activity relationship (SAR) studies have further elucidated the importance of the chloro-fluoro substitution pattern on the phenyl ring. Computational modeling and X-ray crystallography data indicate that this specific substitution enhances binding affinity to certain biological targets while maintaining favorable pharmacokinetic properties. These insights are driving the design of next-generation drug candidates in multiple therapeutic areas.

In conclusion, (1S)-1-(3-chloro-4-fluorophenyl)ethan-1-amine (CAS: 2413817-92-0) represents a versatile and pharmacologically relevant chiral building block with growing importance in drug discovery. Continued research into its applications and synthetic methodologies is expected to yield novel therapeutic agents across various disease areas, particularly in oncology and central nervous system disorders.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)